Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
Abivax S.A.
Abivax S.A.
AbbVie
Janssen Scientific Affairs, LLC
Oppilan Pharma Ltd
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Takeda
Hutchmed
Janssen Research & Development, LLC
W.L.Gore & Associates
PENTAX Europe GmbH
Integra LifeSciences Corporation
Avaxia Biologics, Incorporated
AM-Pharma
Prometheus Laboratories